Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

No significant difference in recurrence rates among women with DCIS taking...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

Treating women with endocrine-resistant HR /HER2 advanced breast cancer

Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie...

Treating women with endocrine-resistant HR /HER2 advanced breast cancer ( Dr Mario Campone - René Gauducheau Centre de Recherche en Cancérologie, Nantes, France. )

No significant difference in recurrence rates among women with DCIS taking...

Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United...

No significant difference in recurrence rates among women with DCIS taking anastrozole or tamoxifen ( Prof Jack Cuzick - Wolfson Institute of Prevention Medicine, London, United Kingdom )

Patients with DCIS receiving anastrozole reported symptoms different from those...

Prof Patricia Ganz - UCLA, Los Angeles, USA

Patients with DCIS receiving anastrozole reported symptoms different from those receiving tamoxifen both groups reported similar quality of life ( Prof Patricia Ganz - UCLA, Los Angeles, USA )

Estrogen receptor mutations detected in plasma associated with worse overall...

Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA

Estrogen receptor mutations detected in plasma associated with worse overall survival in metastatic breast cancer ( Dr Sarat Chandarlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )

Improved survival outcomes in women with HER2-negative breast cancer after...

Dr Masakazu Toi - Kyoto university, Kyoto, Japan

Improved survival outcomes in women with HER2-negative breast cancer after neoadjuvant chemotherapy ( Dr Masakazu Toi - Kyoto university, Kyoto, Japan )

Adding carboplatin to presurgery chemotherapy improved disease-free survival...

Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany

Adding carboplatin to presurgery chemotherapy improved disease-free survival for patients with triple-negative breast cancer ( Prof Gunter von Minckwitz - German Breast Group, Neu-Isenburg, Germany )

Mastectomy plus reconstruction has higher complication rates and costs than...

Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center...

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )

Analysis of blood samples finds ESR1 gene mutations are prevalent and...

Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA

Analysis of blood samples finds ESR1 gene mutations are prevalent and associated with worse overall survival ( Dr Sarat Chanderlapaty - Memorial Sloan Kettering Cancer Center, New York, USA )

Breast-conserving therapy yielded better outcomes than mastectomy for early...

Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht...

Breast-conserving therapy yielded better outcomes than mastectomy for early-stage patients ( Dr Sabine Siesling - Netherlands Comprehensive Cancer Organisation, Utrecht, Netherlands )

Mastectomy plus reconstruction has higher complication rates and costs than...

Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center...

Mastectomy plus reconstruction has higher complication rates and costs than lumpectomy plus radiation ( Prof Benjamin D. Smith - The University of Texas MD Anderson Cancer Center, Houston, USA )

Denosumab improves disease-free survival for postmenopausal patients with HR...

Prof Michael Gnant - Medical University of Vienna, Vienna, Austria

Denosumab improves disease-free survival for postmenopausal patients with HR-positive breast cancer ( Prof Michael Gnant - Medical University of Vienna, Vienna, Austria )

More from ecancer